Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
Open Access
- 3 May 2020
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (11) , 2274-2285
Abstract
Aims: Adalimumab‐adbm is a monoclonal antibody developed as a biosimilar to adalimumab (Humira, AbbVie Inc.). The key objectives of this study were using a population pharmacokinetic (PPK) approach to assess pharmacokinetic (PK) similarity between adalimumab‐adbm and Humira in patients with active rheumatoid arthritis (RA), to quantify the effects of potential covariates on adalimumab PK and to assess the impact of switching treatment from Humira to adalimumab‐adbm on PK.Methods: A PPK model was firstly developed using intensive PK data from the phase‐1 study in healthy subjects (NCT02045979). PPK models were developed separately for phase‐3 base study (NCT02137226) and its extension study (NCT02640612) in patients with active RA.Results: PPK models were developed for adalimumab from adalimumab‐adbm and Humira treatment in healthy subjects and RA patients. Weight and anti‐drug antibodies were found to be important predictors of adalimumab clearance. Adalimumab PK was similar between adalimumab‐adbm and Humira. The estimated effect of Humira on clearance, relative to the adalimumab‐adbm, was 1.02 (i.e., Humira has 0.02 greater clearance). Similarly, the effect of treatment arms (switching) on clearance was estimated to be 1.00 and 0.997 for Humira:Humira:BI and Humira:BI:BI arms, respectively, relative to the BI:BI:BI arm (BI refers to adalimumab‐adbm) in the phase‐3 extension study.Conclusion: PK similarity between adalimumab‐adbm and Humira in patients with active RA was demonstrated using PPK approach. Adalimumab PK was also similar when switching treatment from Humira to adalimumab‐adbm at either week 24 or 48.Keywords
This publication has 21 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Immunogenicity to Therapeutic Proteins: Impact on PK/PD and EfficacyThe AAPS Journal, 2012
- Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects ModelingClinical Pharmacology & Therapeutics, 2011
- Population Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Kinetics of FcRn-mediated recycling of IgG and albumin in human: Pathophysiology and therapeutic implications using a simplified mechanism-based modelClinical Immunology, 2007
- The Utility of the Population Approach Applied to Bioequivalence in PatientsTherapeutic Drug Monitoring, 2005
- A Size Standard for PharmacokineticsClinical Pharmacokinetics, 1996